Department of Oncology and Advanced Technologies, Oncology Unit, Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy
Department of Oncology and Advanced Technologies, Oncology Unit, Azienda Ospedaliera S.Maria Nuova/IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Anticancer Res. 2014 Sep;34(9):5105-10.
To retrospectively evaluate sorafenib activity and safety in patients with metastatic thymic carcinoma (TC) and to correlate outcome with c-KIT and PDGFR-alpha mutational status.
Patients with metastatic thymic carcinoma treated with sorafenib after at least one prior line of chemotherapy were included. Objective response rate (ORR) and toxicity were evaluated. Analysis of c-KIT and PDGFR-alpha mutational status was performed retrospectively.
From October 2007 to August 2011, 5 patients with metastatic thymic carcinoma were evaluated. A median of 8 cycles of sorafenib (range=3-29) were administered. Two patients (40%) displayed a partial response (PR), two patients presented stable disease (SD), while one patient had progression. The median progression-free (PFS) and overall survival were 28 weeks and 92 weeks, respectively. At mutational analysis, only one patient with PR had c-KIT mutation in exon 17 and was successfully treated with sunitinib for 12 months after progression to sorafenib. No PDGFR-alpha mutations were found.
Sorafenib activity seems independent from the c-KIT and PDGFR-alpha mutational status. After progression, sequence treatment with a different tyrosine kinase inhibitor can be considered. These results are promising and need further confirmation on larger, possibly prospective, series of patients.
回顾性评估索拉非尼治疗转移性胸腺癌（TC）患者的疗效和安全性，并分析 c-KIT 和 PDGFR-α 突变状态与预后的相关性。
回顾性分析 2007 年 10 月至 2011 年 8 月间接受索拉非尼治疗的至少一线化疗后进展的转移性胸腺癌患者。评估客观缓解率（ORR）和毒性。对 c-KIT 和 PDGFR-α 突变状态进行分析。
共纳入 5 例转移性胸腺癌患者。中位索拉非尼治疗周期为 8 个周期（范围 3-29 个周期）。2 例患者（40%）获得部分缓解（PR），2 例患者病情稳定（SD），1 例患者疾病进展。中位无进展生存期（PFS）和总生存期（OS）分别为 28 周和 92 周。在突变分析中，只有 1 例 PR 患者在 c-KIT 外显子 17 中存在突变，并在进展至索拉非尼后成功接受舒尼替尼治疗 12 个月。未发现 PDGFR-α 突变。
索拉非尼的疗效似乎与 c-KIT 和 PDGFR-α 突变状态无关。在疾病进展后，可考虑序贯使用不同的酪氨酸激酶抑制剂进行治疗。这些结果令人鼓舞，需要进一步在更大、可能是前瞻性的患者系列中进行验证。
